Document Detail

How to optimize HCV therapy in genotype 4 patients.
MedLine Citation:
PMID:  23286845     Owner:  NLM     Status:  In-Data-Review    
HCV is a worldwide disease with an estimated prevalence by WHO of 3%. Hepatitis C virus 4 is prevalent in Africa and the Middle East, especially Egypt. The treatment of HCV4 is affected by many factors, related to the virus itself (genotype, pretreatment viral load and prevalent quasispecies), to the host (genetic factors, age, ethnicity and liver histology), to the presence of comorbidities (obesity, insulin resistance and co-infections) and to the therapeutic drugs (type, dose and duration). Optimizing treatment is the goal of daily practice to obtain the best results for the patient.
Gamal Esmat; Mohamed El Kassas; Mohamed Hassany; Mohamed Esmat Gamil; Maisa El Raziky
Related Documents :
24759055 - Anonymous hiv testing: what does it mean in policy and practice? a case study in newfou...
16546785 - Living with hiv: the psychological relevance of meaning making.
24810965 - Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in p...
21876215 - Moving from viral suppression to comprehensive patient-centered care: the high prevalen...
22678465 - Chronic hcv infection was associated with severe insulin resistance and mild atheroscle...
7922775 - Serum ige levels in liver cirrhosis. contrasting results in alcoholic and non-alcoholic...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  41-5     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How to optimize HCV therapy in genotype 2 patients.
Next Document:  How to optimize HCV therapy in genotype 1 patients with cirrhosis.